Alendronate treatment in osteogenesis imperfecta

Journal of Clinical Rheumatology

Volumn 12, Issue 2, 2006, Pages 53-56

  Madenci, Ercan ^a   Yilmaz, Kutluhan ^a   Yilmaz, Mustafa ^a   Coskun, Yavuz ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Alendronate; Bisphophonates; Osteogenesis imperfecta; Treatment

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; PARATHYROID HORMONE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY HEIGHT; BONE DENSITY; CASE REPORT; CHILD; CONCENTRATION (PARAMETERS); DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FOREARM; FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; LABORATORY TEST; LUMBAR SPINE; MALE; MOBILIZATION; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL;

ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; DENSITOMETRY, X-RAY; FEMALE; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE; RADIUS; TREATMENT OUTCOME; ULNA;

EID: 33748142395     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000208490.22492.09     Document Type: Article

References (17)

1. Wright NM. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis. J Pediatr Endocrinol Metab. 2000;13:999-1002.
2. Nishi Y, Hamamoto K, Kajiyama M, et al. Effect of long-term calcitonin therapy by injections and nasal spray on the incidence of fracture in osteogenesis imperfecta. J Pediatr. 1992;121:477-480.
3. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952.
4. Plotkin H, Rauch F, Bishop N, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846-1850.
5. Adami S, Gatti D, Colapietro F, et al. Intravenous etidronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18:126-130.
6. Demir E, Bereket A, Ozkan B, et al. Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J Pediatr Endocrinol Metab. 2000;13:217-221.
7. Buchman AL. Metabolic bone disease in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2002;5:173-180.
8. Bereket A, Erdogan T. Oral bisphosphonate therapy for vitamin D intoxication of the infant. Pediatrics. 2003;111:899-901.
9. Bundak R, Buyume NO. In: Neyzi O, Ertugrul T, eds. Pediatrics, vol 1. Nobel Kitabevi; 2002:91-99.
10. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr. 2003;92:452-455.
11. Dimeglio LA, Ford L, McClintock C, et al. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2005;18:44-53.
12. Pizones J, Plotkin H, Parra-Garcia JI, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop. 2005;25:332-335.
13. Rauch F, Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med. 2005;37:295-302.
14. Peter C, Rodan GA. Preclinical safety profile of alendronate. Int J Clin Pract. 1999;101:3-8.
15. Malik AR, Campbell SH, Toma NM. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol. 2002;86:1443.
16. Evans KD, Lau ST, Oberbauer AM, et al. Alendronate affects long bone length and growth plate morphology in the OIM mouse model for osteogenesis imperfecta. Bone. 2003;32:268-274.
17. Gomez-Garcia L, Esbrit P, Carreno L, et al. Alendronate interacts with the inhibitory effect of 1,25(OH)2D3 on parathyroid hormone-related protein expression in human osteoblastic cells. J Bone Miner Res. 2003;18:78-87.